Approval · Notice of Compliance 22666 · 2019
MINT-IMATINIB: Notice of Compliance 22666
Issued September 18, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22666
- Date
- September 18, 2019
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- GLEEVEC (Novartis Pharmaceuticals Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-IMATINIB | 02492334 | Marketed |
| MINT-IMATINIB | 02492342 | Marketed |
Medicinal ingredients
- IMATINIB MESYLATE 100 MG per TAB
- IMATINIB MESYLATE 400 MG per TAB